SEC Comment Letter 0000000000-24-004386 to TFF Pharmaceuticals, Inc. (TFFP) (CIK 0001733413)
TFF Pharmaceuticals, Inc. (TFFP) (CIK 0001733413)
Date: April 22, 2024 · CIK: 0001733413 · Accession: 0000000000-24-004386
AI Filing Summary & Sentiment
File numbers found in text: 333-278807
Letter
United States securities and exchange commission logo April 22, 2024 Harlan Weisman, MD Chief Executive Officer TFF Pharmaceuticals, Inc. 1751 River Run, Suite 400 Fort Worth, Texas 76107 Re:TFF Pharmaceuticals, Inc. Registration Statement on Form S-1 Filed April 18, 2024 File No. 333-278807 Dear Harlan Weisman: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Tamika Sheppard at 202-551-8346 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Daniel K. Donahue
Show Raw Text
United States securities and exchange commission logo
April 22, 2024
Harlan Weisman, MD
Chief Executive Officer
TFF Pharmaceuticals, Inc.
1751 River Run, Suite 400
Fort Worth, Texas 76107
Re:TFF Pharmaceuticals, Inc.
Registration Statement on Form S-1
Filed April 18, 2024
File No. 333-278807
Dear Harlan Weisman:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Tamika Sheppard at 202-551-8346 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Daniel K. Donahue